July 9, 2021
Finally, a drug for Alzheimer’s?
The US Food and Drug Administration (FDA) approved aducanumab, the first new drug for Alzheimer’s disease in 18 years.
Tomorrow's Science For Today's Clinician
Tomorrow's Science For Today's Clinician
The US Food and Drug Administration (FDA) approved aducanumab, the first new drug for Alzheimer’s disease in 18 years.
The Pharmacovigilance Risk Assessment Committee (PRAC) of EMA has concluded that the benefits of ifosfamide solutions for infusion continue to outweigh their risks in the treatment of different types of cancers, including various solid tumours and blood cancers such as lymphomas.
In a study funded by the National Institutes of Health (NIH), researchers tested a novel combination treatment approach on mice with tumours with characteristics similar to human astrocytomas — a type of slow-growing glioma—and found tumour regression in 60 percent of the mice treated.
Cyanobacteria are promising but still unexplored natural resources offering a wealth of chemicals for the discovery of pharmaceutical compounds and new drugs.
The US FDA has requested manufacturers withdraw all prescription and over-the-counter (OTC) ranitidine drugs from the market immediately.
A novel tetravalent dengue vaccine candidate developed by Takeda is found demonstrating similar degrees of protection in individuals who had and had not been previously infected with dengue.
Entacapone, the commonly used medication for Parkinson’s disease is not associated with increased risk of prostate cancer, said USFDA, confirming…
The European Medicines Agency (EMA) has recommended that the multiple sclerosis medicine fingolimod (Gilenya) must not be used in pregnant…
Two drugs have emerged potential future treatments against Ebola virus demonstrating a cure rate of up to 90% in an…
The Union government has mooted a proposal to make it mandatory for all generic medicine manufacturers to print the generic names of drugs on the labels larger than the brand or trade names.